Ipsen (Ipsen)

Oncology Corporate Profile

Company Description

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.

Website: http://www.ipsen.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
somatulinesomatostatin analog inhibitorNeuroendocrine tumorIII
decapeptyl (triptorelin pamoate)decapeptide analogueProstate cancerIII
tasquinimodoral quinolone-3-carboxamidProstate cancerIIActive Biotech
tasquinimodoral quinolone-3-carboxamidVarious cancer typesII

View additional information on product candidates here »

Source


http://www.ipsen.com

Recent News Headlines

There are no news items to display